Obstetrics and Gynecology
ReachMD
Episodes
Consensus Recommendations for Use of p16/Ki67 Dual Staining Cytology in the Management of Individuals Testing Positive for HPV
5/29/2024
Host: Warner K. Huh, MD
Guest: Kimberly Levinson, MD, MPH
More effective triage tests are essential to improving cervical cancer risk-stratification and thus reducing the potential for unnecessary colposcopies. Enduring consensus cervical cancer screening recommendations, published in 2024, describe specific-use algorithms for p16/Ki-67 dual-staining cytology as an effective triage test, and also offer insight on how this test can best fit into clinical practice. Join Drs. Warner Huh and Kimberly Levinson as they first establish the rationale for using p16/Ki-67 dual-staining cytology and then break down the most salient algorithms for its use as offered in the recent recommendations.
Duration:00:12:15
Gastrointestinal and Hematologic TEAEs Related to ADC Therapy in Gynecologic Cancers
3/19/2024
Host: Susana Campos, MD, MPH
"Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Duration:00:05:00
ADCs in Gynecologic Cancers: Managing Pulmonary and Cardiac TEAEs
3/19/2024
Host: Susana Campos, MD, MPH
"Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Duration:00:05:30
Emerging ADC Therapies for NSCLC: Anticipating AEs Reported in Clinical Trials
3/19/2024
Host: Egbert Smit, MD
"Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Duration:00:04:59
ADC-Related Hematologic Adverse Events
3/19/2024
Host: Egbert Smit, MD
"Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Duration:00:04:59
Optimal Management of ADC-Related Gastrointestinal AEs in NSCLC
3/19/2024
Host: Egbert Smit, MD
"Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Duration:00:04:59
Managing ADC-Related Pulmonary and Cardiac AEs in NSCLC
3/19/2024
Host: Egbert Smit, MD
"Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Duration:00:05:30
ADCs on the Horizon for Breast Cancer: Managing Treatment-Emergent Toxicities
3/19/2024
Host: Nadia Harbeck, MD, PhD
"Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Duration:00:03:59
Hematologic Adverse Events With ADCs in Breast Cancer: Optimal Management Strategies
3/19/2024
Host: Nadia Harbeck, MD, PhD
"Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Duration:00:05:00
Risk Reduction and Management Protocols for Gastrointestinal Adverse Events With ADC Therapy in Breast Cancer
3/19/2024
Host: Nadia Harbeck, MD, PhD
"Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Duration:00:04:29
Managing Pulmonary and Cardiac Adverse Events Related to ADC Therapy in Breast Cancer
3/19/2024
Host: Nadia Harbeck, MD, PhD
"Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Duration:00:06:29
Patient-Centric Approaches to Managing Migraines in the Female Patient
2/13/2024
Host: Jessica Ailani, MD
Guest: Dawn C. Buse, PhD
Half of the women in the US with migraine are never diagnosed. Of those who are, the journey to effective treatment may last a decade or longer. But newer and more effective targeted treatments are beginning to make a difference. Join Drs. Jessica Ailani and Dawn Buse as they discuss a novel approach to managing migraine and interview a patient whose migraine journey is unfortunately one traversed by many women.
Duration:00:14:30
Migraine and Women's Health: Migraine and the Whole Female Patient
12/5/2023
Host: Jessica Ailani, MD
Guest: Dawn C. Buse, PhD
Upwards of 47 million people in the U.S. suffer from migraines, often accompanied by widespread personal, professional, and social disabilities. Though a similar prevalence is initially observed between men and women, by mid-adulthood the prevalence of migraine is 3-fold greater in women than men. Newer agents, both injectable and oral and focused on modulating the calcitonin gene-related peptide pathway, have emerged and have proven highly effective in managing both acute and chronic migraine. Join Drs. Jessica Ailani and Dawn Buse as they provide an overview of the changing landscape of migraine therapy, especially as it impacts women across different life-stages.
Duration:00:53:27
Postpartum Depression: A Significant Burden and a Novel Approach to Treatment
12/5/2023
Host: Lee Shulman MD, FACOG, FACMG
Guest: Kristina Deligiannidis, MD
The recent development and approval of two neuroactive steroids is likely to change the treatment paradigm for moderate to severe postpartum depression (PPD). These agents have a quick onset and function as GABAA positive allosteric modulators. Join Drs. Shulman and Deligiannidis as they address the burdens and impacts of PPD on mothers, babies, and partners, and deep dive into the pathophysiologic role and clinical findings associated with the use of neuroactive steroids in the management of PPD.
Duration:00:36:29
Taking the Patient-Centered Approach to Mycophenolate Risk Mitigation
11/30/2023
Guest: Cara Dolin, MD
Guest: Jennifer Simpson
Guest: Diana Girnita, MD ,PhD
Explore this video roundtable featuring an interdisciplinary panel of experts discussing a woman’s journey with mycophenolate therapy and strategies to approach risk mitigation. Learn more about how to provide critical education on the risks of mycophenolate, the importance of effective contraception, and navigating family planning.
Duration:00:52:58
Hot Topics in Blood-based Cancer Screening: Key Information on Multi-Cancer Early Detection from 2023 Spring Oncology Meetings
8/10/2023
Guest: Candace T. Westgate, DO, MPH, FACOG
Guest: Ethan D. Schram, MD, FACP
Early detection of cancer is essential to reducing the significant burdens associated with it. When cancer is detected at earlier stages, treatments can be initiated sooner, resulting in improved outcomes, reduced morbidity and mortality, and better quality of life. While the implementation of current screening guidelines has resulted in an overall reduction in cancer deaths, only 25 percent of cancers are diagnosed using traditional screening modalities, leaving much room for improvement. Blood-based multi-cancer early detection, or MCED, tests that can screen from four to greater than 50 types of cancers have been developed to complement the population-based screening of asymptomatic individuals. At the spring 2023 American Association for Cancer Research, also known as AACR, American Society of Clinical Oncology, or ASCO, and National Comprehensive Cancer Network, orNCCN, annual conferences, a multitude of data was presented on MCEDs, including real-world data, clinical trial data, novel MCEDs in development, MCED accuracy, and the inherent health equity challenges that their implementation will face. This educational activity has two parts. Dr. Candace Westgate delivers an MCED Primer designed to build primary care clinicians’ knowledge about the science of MCEDs and how to implement their use in primary care practice, followed by chapterized discussions between …
Duration:00:59:51
Alloimmune Thrombocytopenia in the Fetus and Newborn
11/23/2022
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: James B. Bussel, MD
This program is no longer available for credit.
Program Chairman:
Roberto Romero, MD, DMedSci
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology
As the platelet equivalent of hemolytic disease of the fetus and newborn, fetal and neonatal alloimmune thrombocytopenia (FNAIT) is an uncommon yet complex and life-threatening bleeding disorder that results from incompatibility between mother and baby for platelet-specific antigens. Despite relatively normal platelet function, in the setting of severe thrombocytopenia, intracranial hemorrhage is a consequence. Drs. Shulman and Bussel discuss advances in management strategies and concrete steps you can take to lower the risk and stop the progression of this disorder in your patients.
Duration:00:18:28
Targeting the Fc Receptor Pathway to Treat Red Blood Cell Alloimmunization
10/27/2022
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Kenneth J. Moise Jr., MD
This program is no longer available for credit.
Program Chairman:
Roberto Romero, MD, DMedSci
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology
How well do you understand the biology of hemolytic disease of the fetus and newborn (HDFN)? What about its connection to the FcRn receptor pathway and IgG? Drs. Lee Shulman and Ken Moise go beyond the basics taught in medical school immunology and look more closely at FcRn’s role in protecting IgG. With an improved understanding of these mechanisms, we can expand therapeutic targets beyond the fetus and newborn and finally put the needles away.
Duration:00:12:39
Red Blood Cell Alloimmunization, Pathophysiology, Diagnosis, Treatment, and Prevention
9/30/2022
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Kenneth J. Moise Jr., MD
This program is no longer available for credit.
Program Chairman:
Roberto Romero M.D. D.Med Sci.
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology
Are you taking the right steps to consistently ensure all of your patients at risk of alloimmune disorders of pregnancy, specifically HDFN, receive a helping hand plus timely and appropriate clinical care? Despite having considerable clinical consequences, this area of medicine is not fully understood by many clinicians. Drs. Shulman and Moise provide expert insight on red blood cell alloimmunization, highlighting essential pathophysiology and current and evolving management strategies. Join us to learn new ways to approach this complicated and rare clinical condition.
Duration:00:13:59
Fertility Preservation Options for Women
11/25/2013
Host: Prathima Setty, MD
Fertility preservation technologies have become more advanced and more accessible over the past several years. Joining host Dr. Prathima Setty to discuss current options for women to protect their fertility is Dr. Naveed Khan, Reproductive Endocrinology and Infertility Specialist in Leesburg, VA. Dr. Khan practices with Shady Grove Fertility, the nation's largest fertility center, and is also a member of the American College of Obstetrics and Gynecology and the American Society of Reproductive Medicine.
Duration:00:14:58